^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MB-CAR-T19-22

    i
    Other names: MB-CAR-T19-22
    Associations

    News

    Trials
    Company:
    Miltenyi Biotec
    Drug class:
    CD19-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    almost2years
    Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL (clinicaltrials.gov)
    P1/2, N=50, Active, not recruiting, Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Mar 2027 | Trial primary completion date: Dec 2022 --> Mar 2022
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CD22 (CD22 Molecule)
    |
    CD19 expression • CD22 expression
    |
    cytarabine • cyclophosphamide • etoposide IV • dexamethasone • fludarabine IV • Actemra IV (tocilizumab) • MB-CAR-T19-22